2023 U.S. Department of Veterans Affairs and U.S. Department of Defense Clinical Practice Guideline for the Management of Headache

The revised CPG includes 52 recommendations on evaluation, pharmacotherapy, invasive interventions, and nonpharmacologic interventions for selected primary and secondary headache disorders. In addition to triptans and aspirin-acetaminophen-caffeine, newer calcitonin gene-related peptide (CGRP) inhibitors (gepants) are options for treatment of acute migraine. Medications to prevent episodic migraine (EM) include angiotensin-receptor blockers, lisinopril, magnesium, topiramate, valproate, memantine, the newer CGRP monoclonal antibodies, and atogepant. AbobotulinumtoxinA can be used for prevention of chronic migraine but not EM. Gabapentin is not recommended for prevention of EM. Ibuprofen (400 mg) and acetaminophen (1000 mg) can be used for treatment of TTH, and amitriptyline for prevention of chronic TTH. Physical therapy or aerobic exercise can be used in management of TTH and migraines.

Authors

Institutions

Publication Details

Journal
Annals of Internal Medicine
Published
2024-10-28
DOI
https://doi.org/10.7326/annals-24-00551
Citations
9
Primary Topic
Migraine and Headache Studies
Type
article
Field-Weighted Citation Impact
3.47
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

2023 U.S. Department of Veterans Affairs and U.S. Department of Defense Clinical Practice Guideline for the Management of Headache

James Reston, Andrew Buelt, Karen M. Skop, Jason J. Sico et al.
9 citations
Annals of Internal Medicine
Migraine and Headache Studies
3.47
article

2023 U.S. Department of Veterans Affairs and U.S. Department of Defense Clinical Practice Guideline for the Management of Headache

James Reston, Andrew Buelt, Karen M. Skop, Jason J. Sico, Natasha Antonovich, Franz J. Macedo, Amanda Ford, Thomas R. Stark, Friedhelm Sandbrink, Jennifer Ballard‐Hernandez, Amy S. Grinberg, James Sall, Rebecca Vogsland, Lisa Wayman, Ian W. Pace
article en
9 citations

Abstract

The revised CPG includes 52 recommendations on evaluation, pharmacotherapy, invasive interventions, and nonpharmacologic interventions for selected primary and secondary headache disorders. In addition to triptans and aspirin-acetaminophen-caffeine, newer calcitonin gene-related peptide (CGRP) inhibitors (gepants) are options for treatment of acute migraine. Medications to prevent episodic migraine (EM) include angiotensin-receptor blockers, lisinopril, magnesium, topiramate, valproate, memantine, the newer CGRP monoclonal antibodies, and atogepant. AbobotulinumtoxinA can be used for prevention of chronic migraine but not EM. Gabapentin is not recommended for prevention of EM. Ibuprofen (400 mg) and acetaminophen (1000 mg) can be used for treatment of TTH, and amitriptyline for prevention of chronic TTH. Physical therapy or aerobic exercise can be used in management of TTH and migraines.

Annals of Internal MedicineVol. 177(12)
ECRI Institute (US), Brooke Army Medical Center (US), Wright-Patterson Air Force Base (US), Edward Hines, Jr. VA Hospital (US), VA Connecticut Healthcare System (US), James A. Haley Veterans' Hospital (US), Bay Pines VA Healthcare System (US), Minneapolis VA Health Care System (US), United States Army Institute of Surgical Research (US), Office of Patient Care Services (US), Minneapolis VA Medical Center (US), South Texas Veterans Health Care System (US), Washington DC VA Medical Center (US), Joint Base San Antonio (US)
Openalex Percentile: Top 6%
Migraine and Headache Studies
3.47
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.